These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 19336831)

  • 1. Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection.
    Yost R; Pasquale TR; Sahloff EG
    Am J Health Syst Pharm; 2009 Apr; 66(8):715-26. PubMed ID: 19336831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maraviroc: a review of its use in the management of CCR5-tropic HIV-1 infection.
    Perry CM
    Drugs; 2010 Jun; 70(9):1189-213. PubMed ID: 20518583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
    Lieberman-Blum SS; Fung HB; Bandres JC
    Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir.
    Westby M; Lewis M; Whitcomb J; Youle M; Pozniak AL; James IT; Jenkins TM; Perros M; van der Ryst E
    J Virol; 2006 May; 80(10):4909-20. PubMed ID: 16641282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing the Diverse Mutational Pathways Associated with R5-Tropic Maraviroc Resistance: HIV-1 That Uses the Drug-Bound CCR5 Coreceptor.
    Jiang X; Feyertag F; Meehan CJ; McCormack GP; Travers SA; Craig C; Westby M; Lewis M; Robertson DL
    J Virol; 2015 Nov; 89(22):11457-72. PubMed ID: 26339063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of maraviroc.
    Parra J; Portilla J; Pulido F; Sánchez-de la Rosa R; Alonso-Villaverde C; Berenguer J; Blanco JL; Domingo P; Dronda F; Galera C; Gutiérrez F; Kindelán JM; Knobel H; Leal M; López-Aldeguer J; Mariño A; Miralles C; Moltó J; Ortega E; Oteo JA
    Clin Drug Investig; 2011; 31(8):527-542. PubMed ID: 21595497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
    Hardy WD; Gulick RM; Mayer H; Fätkenheuer G; Nelson M; Heera J; Rajicic N; Goodrich J
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):558-64. PubMed ID: 20703158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Maraviroc efficacy in clinical studies on the development of the molecule].
    Moreno S; Hernández B; Gutiérrez C; Delsol E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():17-22. PubMed ID: 19133217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Pharmacokinetics, interactions and mechanism of action of maraviroc].
    Soriano V; Poveda E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():12-6. PubMed ID: 19133216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
    Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
    J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maraviroc: a new CCR5 antagonist.
    Sayana S; Khanlou H
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maraviroc.
    Fadel H; Temesgen Z
    Drugs Today (Barc); 2007 Nov; 43(11):749-58. PubMed ID: 18174962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
    Saag M; Goodrich J; Fätkenheuer G; Clotet B; Clumeck N; Sullivan J; Westby M; van der Ryst E; Mayer H;
    J Infect Dis; 2009 Jun; 199(11):1638-47. PubMed ID: 19432546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
    Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
    Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maraviroc: a review of its use in HIV infection and beyond.
    Woollard SM; Kanmogne GD
    Drug Des Devel Ther; 2015; 9():5447-68. PubMed ID: 26491256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
    Bredeek UF; Harbour MJ
    Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study.
    Recordon-Pinson P; Soulié C; Flandre P; Descamps D; Lazrek M; Charpentier C; Montes B; Trabaud MA; Cottalorda J; Schneider V; Morand-Joubert L; Tamalet C; Desbois D; Macé M; Ferré V; Vabret A; Ruffault A; Pallier C; Raymond S; Izopet J; Reynes J; Marcelin AG; Masquelier B;
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3335-40. PubMed ID: 20530226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maraviroc for previously treated patients with R5 HIV-1 infection.
    Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
    N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
    Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.